IRCT20200503047281N1
Not yet recruiting
Early Phase 1
Evaluation of Convalescent Plasma Therapy for COVID-19 Patients
Yazd University of Medical Sciences0 sites40 target enrollmentTBD
Overview
- Phase
- Early Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yazd University of Medical Sciences
- Enrollment
- 40
- Status
- Not yet recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •age between 20 to 60 years old
Exclusion Criteria
- •People with a history of other immune, genetic or infectious diseases other than corona
- •Individual suspended but negative for clinical standard covid\-19 test
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patientsIRCT20200406046968N2Tabriz University of Medical Sciences30
Completed
Phase 2
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/04/024706Institute of Liver and Biliary Sciences29
Recruiting
Not Applicable
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical TrialCOVID-19.Coronavirus infection, unspecifiedB34.2IRCT20181104041551N1Mazandaran University of Medical Sciences30
Completed
Phase 3
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/06/025803Institute of Liver and Biliary Sciences400
Completed
Phase 2
Efficacy of Combined Convalescent Plasma Therapy with Oral RNA-dependent RNA Polymerase Inhibitor versus Monoclonal Neutralizing Antibody Therapy among Mild to Moderate COVID-19 in Outpatients: Multicenter, Non-inferiority, Open-label Randomized Controlled TrialMild to moderate COVID-19 (non-severe COVID-19)COVID-19, SARS-CoV-2, favipiravir, sotrovimab, convalescent plasma therapy, monoclonal neutralizing antibodyTCTR20220319002Chulabhorn Royal Academy136